Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

Experienced executive with over 3 decades of progressive experience, ranging from frontline sales to key executive leadership positions in ophthalmology industry.

Associated with Alcon® Laboratories India Pvt Ltd, A global leader in eyecare for over 28 years from 1992 – 2020 across various key positions in sales and marketing management, commercial Excellence, business development, strategic planning, and orchestrated several successful launches with sustained growth of a diverse top-of-the-line Cataract, Vitreoretinal & Refractive portfolio, ensuring market leadership position. (Eg: AcrySof® IOLs portfolio, Centurion® Vision system, Constellation® Vitrectomy system, WaveLight® lasers and more) Pan-India market.

Associated with Biotech Vision care Pvt Ltd, a leading India/Ireland-based manufacturer of Phakic IOLs, Cataract IOLs portfolio, OVDs etc from 2021 – 2025(5 years) in the capacity as Cluster Head, managing distributors operations in APAC and LATAM markets, along with direct markets in India and Brazil, driving GTM strategy and double digit sales growth.

Q2. How is demand for ophthalmic products evolving across India, APAC, and LATAM, and what are the key drivers behind these shifts?

Demand for ophthalmic products is rising sharply.  India and APAC are experiencing rapid growth, while LATAM is expanding steadily as healthcare infrastructure improves. The key drivers behind these shifts are:

1. Global demographic trends show a rapidly growing aging population with longer life expectancy, creating a need for Cataract, Vitreoretinal, and Refractive surgeries to address active lifestyle-driven requirements for spectacle independence
2. Increasing prevalence of cataract and refractive disorders & expanding access to eye care in rural markets.
3. Latest technological advancements: Growing access to advanced diagnostics, surgical equipment, and premium intraocular lenses (IOLs) is transforming cataract and refractive surgery into highly predictable, patient-tailored procedures with superior outcomes.
4. The skill level of ophthalmic surgeons has improved dramatically in the last 2 decades, thanks to a combination of structured training, technological advances, global exposure, and continuous professional development.
5. Market awareness: Cataract surgery is widely regarded as one of the most successful surgical procedures in modern medicine, with success rates exceeding 95–98% with quick recovery within a few days consistently delivers dramatic improvements in vision and improved quality of life.

Q3. How are go-to-market strategies evolving across regions with very different channel structures and customer behaviours?

Ophthalmic GTM strategies are shifting from physician-centric to hybrid, patient-inclusive, and digitally enabled models, with challenges in approach to reshaping care models, technology adoption, and patient expectations.

• Private ophthalmic clinic, Key accounts, Hospital chain-driven, Government hospitals- fragmented across mature and emerging markets
• Premium technologies like trifocal and EDOF lenses promise better patient outcomes but face adoption hurdles due to cost sensitivity and surgeon training gaps. A tiered strategy makes sense—urban/metropolitan centres can sustain premium offerings where patients are more willing to pay for advanced optics, while tier 2/3 cities benefit from affordable monofocal IOLs that balance accessibility with reliability.
• Rising demand for spectacle independence and lifestyle-driven solutions increases pressure on surgeons to offer advanced options.
• Expansion into tier-2/3 cities and rural outreach.
• Direct-to-patient education campaigns via digital marketing on lifestyle-driven eye care choices.
• Surgeon Training and education programs to expand the adoption of advanced technologies. Hybrid engagement combining in-person detailing with digital CME/webinars, national and international conferences.
• Affordable tiered offerings and distributor partnerships in smaller markets.

Q4. How is the competitive landscape evolving across your key markets, particularly between global players and regional manufacturers?

Global ophthalmic markets are dominated by multinational giants (Alcon, J&J Vision, Hoya), with an estimated 70–75% value market share, primarily driven by INNOVATION, R&D on premium technologies, and combining physician detailing with patient-centric digital campaigns.

Regional manufacturers (e.g., Aurolab, Appawamy, Care Group, Biotech, etc.) are gaining ground rapidly with cost-effective, affordable entry- to mid-level IOLs; however, limited brand equity and apathy are stunting the adoption of their premium IOL technologies. They have strong penetration in Government tenders and distributor management across global markets, with offerings at the entry- to mid-level.

The competitive landscape is now a dual-track race: premium innovation vs. affordability-driven expansion.

Q5. How is AI beginning to influence the way companies identify and prioritize growth opportunities across different markets?

The convergence of AI-driven diagnostics, femtosecond laser precision, surgical planning, and premium IOL technology, combined with workflow automation, is making cataract and refractive surgery more predictable than ever. Patients benefit from personalized visual outcomes, faster recovery, and reduced dependence on glasses.

AI-enabled technologies to detect cataract in mobile clinics in underserved areas and to screen for diabetic retinopathy, which is rapidly rising due to an increase in diabetes prevalence, fuelling the need for retinal imaging.

Q6. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

Growth Trajectory (Last 5–10 Years)

• How consistent has revenue growth been across geographies and product lines?
• What mix of organic vs. inorganic growth has driven performance?

Financial Health & Profitability

• Are margins sustainable given pricing pressures in tier 2/3 markets?
• How resilient is the balance sheet to currency fluctuations and regulatory delays?

Market Access & Commercial Execution

• What is the company’s penetration in urban vs. tier 2/3 cities?
• How effective are distribution networks and after sales support in scaling adoption?

Partnerships & Ecosystem Leverage

• Which KOLs, institutions, and digital health platforms are actively engaged?
• How do these partnerships accelerate surgeon training and patient awareness?

Portfolio & Pipeline (R&D Investment)

• What percentage of revenue is reinvested into R&D?
• How balanced is the pipeline across short term (3 years), medium term (5–6 years), and long term (7–10 years) innovation horizons?

Regulatory & Compliance Readiness

• How prepared is the company to meet evolving MDR/US FDA/Indian CDSCO requirements?
• What systems are in place for post market surveillance and quality assurance?